Mutacin H-29B is identical to mutacin II (J-T8)
Guillaume Nicolas¹, Hélène Morency¹, Gisèle LaPointe² and Marc C Lavoie*³

Address: ¹Département de Biochimie et Microbiologie, Faculté des Sciences et Génie, Université Laval, Quebec, Quebec, G1K 7P4, Canada, ²Centre de Recherche en Sciences et Technologie du Lait (STELA), Institut des Nutraceutiques et des Aliments Fonctionnels (INAF), Faculté des Sciences de l’Agriculture et de l’Alimentation, Université Laval, Québec, G1K 7P4, Canada and ³Department of Biological and Chemical Sciences, Faculty of Pure and Applied Sciences, The University of the West Indies, Cave Hill Campus, Bridgetown, BB 11000, Barbados

Email: Guillaume Nicolas - guillaume.nicolas.1@ulaval.ca; Hélène Morency - helene.morency@bcm.ulaval.ca; Gisèle LaPointe - gisèle.lapointe@aln.ulaval.ca; Marc C Lavoie* - mlavoie@uwichill.edu.bb
* Corresponding author

Abstract

Background: Streptococcus mutans produces bacteriocins named mutacins. Studies of mutacins have always been hampered by the difficulties in obtaining active liquid preparations of these substances. Some of them were found to be lantibiotics, defined as bacterial ribosomally synthesised lanthionine-containing peptides with antimicrobial activity. The goal of this study was to produce and characterize a new mutacin from S. mutans strain 29B, as it shows a promising activity spectrum against current human pathogens.

Results: Mutacin H-29B, produced by S. mutans strain 29B, was purified by successive hydrophobic chromatography from a liquid preparation consisting of cheese whey permeate (6% w/v) supplemented with yeast extract (2%) and CaCO₃ (1%). Edman degradation revealed 24 amino acids identical to those of mutacin II (also known as J-T8). The molecular mass of the purified peptide was evaluated at 3246.08 ± 0.1 Da by MALDI-TOF MS.

Conclusion: A simple procedure for production and purification of mutacins along with its characterization is presented. Our results show that the amino acid sequence of mutacin H-29B is identical to the already known mutacin II (J-T8) over the first 24 residues. S. mutans strains of widely different origins may thus produce very similar bacteriocins.
designed to hybridize with the mutA gene of mutacin II (J-T8) also hybridised with the DNA of strain 29B [11]. We present here a simple procedure for production and purification of mutacin H-29B, along with its partial characterization. The results show that the amino acid sequence of mutacin H-29B is identical to that of mutacin II (J-T8) over the first 24 residues. S. mutans strains of widely different origins may thus produce similar bacteriocins.

Results and discussion
Thermostability and pH stability
The activity of crude preparations of mutacin H-29B, calculated at 6400 AU/ml (Table 1) at pH 4, was not reduced in boiling water (100°C) after 1 h or after autoclaving (121°C, 15 min), but lost 20% of its activity after 2 h at 100°C. All mutacin activity was retained at pH 2–4 after 24 h, but was reduced to 80% at pH 5–7, to 60% at pH 8–9, and to 30% at pH 9–12. These results are in agreement with previously published results obtained on the activity of the mutacin-producing strain S. mutans 29B [10].

Purification and characterization of the mutacin H-29B
Purification of mutacin H-29B was achieved by means of three hydrophobic chromatography steps (Table 1). The final specific activity of the purified mutacin H-29B was 6.4 × 10⁶ AU/mg. As for mutacin II (J-T8) [12,13], the amino acid sequence of the purified mutacin H-29B was blocked at position 9 without alkaline ethanethiol treatment, indicating the presence of modified residues and the lantibiotic nature of mutacin H-29B. This N-terminal sequence was found to be identical to mutacin II (J-T8) [12]. Balakrishnan et al. [14] also reported that mutacin M 19 presents the same N-terminal amino acid sequence. The absence of methionine at the N-terminus suggests that mutacin H-29B may be processed from a precursor form, as reported for lantibiotics in general [9].

Edman degradation performed after alkaline ethanethiol derivatization [15] revealed a total of 24 amino acids. The complete sequence of mutacin H-29B confirms its identity with the mutacin II (J-T8). Modified amino acids were obtained in positions 10, 12, 15, and 19. A BMSEC signal seen as a doublet signal in cycle 10 indicates the presence of an Abu or a dhB [15]. A SEC signal was observed in positions 12, 15, and 19 during sequencing, which indicates the presence of a dhA residue [15]. In each case, the SEC signal was not accompanied by a DSER signal. At this stage, we can not tell if the dhA or Abu residues are implicated or not in the formation of thioether bridges. A deamidation was also observed for the Asn and Gln in positions 1, 5 and 18, which can result from the treatment with alkaline ethanethiol. A Phe residue was observed as a minor amino acid in position 25, probably resulting from the carryover effect of the sequencing procedure.

Comparison of the mutacin H-29B sequence with known bacteriocins revealed the high levels of homology to group AII lantibiotics (Figure 1). However, the TCCS or TCC motif present at the C-terminus of other AII lantibiotics was not detected by Edman degradation for mutacin H-29B. The DNA sequence of the gene coding for mutacin H-29B will confirm whether the TCC motif is also present at the C-terminus of mutacin H-29B.

The molecular mass of mutacin H-29B determined by MALDI-TOF MS (3246.08 ± 0.1 Da) is closely related to the one estimated for mutacin II (J-T8) (3244.64 ± 1.15 Da) [13,16]. This strongly suggested that these two mutacins are identical, including the three terminal amino acids. Thus, the experimentally-demonstrated thioether bridge pattern of mutacin II (J-T8) [16] can be proposed for mutacin H-29B. These would consist of one BM-Lan bridge between the residues in positions 10 (Thr) and 15 (Cys), one Lan bridge between residues 12 (Ser) and 26 (Cys) as well as a second Lan bridge between residues 19 (Ser) and 27 (Cys).

Different strains can produce the same mutacin: S. mutans strains T8, isolated in Australia; UA96, isolated in Alabama, USA; and 29B, isolated in Quebec, Canada [10,17], produce mutacin II (J-T8) ([12,14], this paper); S. mutans strains CH43 and UA140 produce mutacin I [7,18]; and S. mutans JH 1140, isolated in Florida USA [19], and UA787, isolated in Alabama, USA [20], produce the same mutacin, that only differs from mutacin B-Ny266 by only two amino acids [5].

Genes coding for mutacin biosynthesis have all been located on the chromosome so far [7,8,18-22]. The mutacin II (J-T8) gene cluster has been identified and suc-

| Table 1: Purification of mutacin H-29B by hydrophobic chromatography. |
|-----------------|--------|--------|--------|--------|--------|
| Step            | Volume (mL) | Activity (AU/mL) | Total Protein (mg) | Total activity (AU, 10³) | Specific activity (AU/mg) | Yield (%) | Purification (fold) |
| Culture supernatant | 1250     | 6400    | 10000  | 8000   | 800    | 100      | 1                 |
| XAD-7 Amberlite | 300      | 6400    | 97.5   | 1920   | 20000  | 24       | 25                |
| Sep-Pak C₁₈ | 95       | 12800   | 1.9    | 1216   | 6.4 × 10⁴ | 15.2    | 800               |
| C₁₈ RP-HPLC     | 1        | 6.4 × 10⁵ | 0.1    | 640    | 6.4 × 10⁵ | 8       | 8000              |
cessfully transferred to a non-producing strain by transformation [22]. Evolution of the mutacin-lantibiotics from a common ancestor and its propagation via mobile genetic elements is suggested by further observations. A silent transposase gene was reported in the upstream region of the genes coding for mutacin II (J-T8) production [22]. Yonezawa and Kuramitsu (2005) [8] also observed direct repeats sequences flanking the Smb locus with similarity to those of transposase genes directly downstream of the locus. Sequences flanking the Smb locus were found adjacent in the UA159 S. mutans genome (GenBank Accession No AE014133). Mutacin-lantibiotic coding genes could perhaps be transferred via mobile genetic elements.

Conclusion

Mutacin (H-29B) was isolated from an active liquid culture of S. mutans strain isolated in Quebec (29B) and proved to be identical to a previously characterized mutacin II (alias J-T8). Mutacin-lantibiotic production by S. mutans seems to be widespread despite the fact that the reference genome strain for S. mutans (UA159) does not seem to produce any of the mutacin lantibiotics characterized to date.

Methods

Bacterial strains and media

Streptococcus mutans 29B was previously described in Parrot et al. [17] and Micrococcus luteus ATCC 272 was from the American Type Culture Collection (Manassas, VA, USA). They were routinely grown aerobically at 37°C in TSB (Difco laboratories, Detroit, MI, USA) supplemented with 0.3% of Yeast Extract (Becton Dickinson & Co., Cockeysville, MD) (TSBYE) or on TSA (Difco) plates enriched with 0.3% yeast extract (TSAYE).

Mutacin production

An overnight preculture in TSBYE was used to inoculate (1%) 2 L of medium consisting of cheese whey permeate 6% (w/v) (kind gift from Agropur agroalimentary Coop, Granby, QC, Canada) supplemented with 1% CaCO₃ (Anachemia, Montreal, QC, Canada) and 2% yeast extract (Institut Rosell Montreal, QC, Canada) (SWP). The culture was incubated 48 h at 37°C under aerobic conditions [23].

Determination of inhibitory activity

Mutacin activity was determined as describe previously [5] with the following modification: 2-fold dilutions were prepared in acidified (pH 2) peptone water (0.5%) [23]. The specific activity of each preparation was expressed in AU/mg protein. Protein concentration was determined using the BioRad DC protein assay (BioRad, Mississauga, ON, Canada).

Thermostability and pH stability

Crude mutacin (supernatant of SWP medium) was submitted to different pH conditions (pH 2 to pH 11) adjusted with 4 N HCl or 4 N NaOH. After 2 h and 24 h at room temperature, residual mutacin activity was assayed by the spot test described above. Non-inoculated sterile SWP medium adjusted in the same conditions of the tested sample was used as negative control. Thermostability was assayed by determining the residual activity of crude mutacin samples adjusted at pH 4 and placed in boiling water for up to 120 min and after autoclaving.

Mutacin H-29B extraction and purification

After 48 h of incubation at 37°C, the pH of the culture was adjusted to 2.0 with 4 N HCl and incubated for 2 h at room temperature to desorb the mutacin [23]. The culture was then centrifuged at 10,000 × g for 10 min and heated at 70°C for 20 min to destroy the remaining cells and enzyme activity. The purification steps were essentially those previously used for the purification of mutacin B-Ny266 [5] with the following modification: concentration was carried out by adsorption to XAD-7 Amberlite (Sigma Chemical Co., St Louis, MO, USA). Hydrophobic chromatography on Sep-Pak® Vac 35 cc (10 g) t-C₁₈ Cartridges (Waters Corporation, Milford, MA, USA) was performed with the pooled active fractions diluted to 35% in MeOH in 10 mM HCl. Active fractions were recovered with an elution gradient of 50%-60% MeOH in 10 mM HC1. The final purification step was carried out by reverse phase chromatography (RP)-HPLC (Beckman Gold Model, Coulter Canada Inc., Mississauga, ON, Canada) using an analytical C₁₈ column (Luna 5 μ C18(2), 250 × 4.6 mm, 4 × 3.0 mm, Phenomenex, Torrance, CA, USA). Elution was carried out with 5% acetonitrile in 0.1% TFA and 60% acetonitrile in 0.1% TFA and recorded at 214 nm.

Several re-injections of the same sample were made until a unique peak was obtained. Active fractions were dried in a Speed-Vac® concentrator (Model SC110A, Savant Instrument Inc. Farmingdale, NY) and kept at -20°C for further analyses.

Molecular mass determination

Molecular mass was determined for the purified HPLC fraction by MALDI-TOF MS on a Voyager DE-PRO (Applied Biosystems, Foster City, CA, USA) at the Peptide Synthesis & Protein Sequencing Core facility of Eastern Quebec, QC, Canada.

Sequence determination

Automated Edman degradation was performed on a protein sequencer (ABI Procise cLC, Applied Biosystems, Foster City, CA, USA) after alkaline ethanolol derivatization [15]. Pure mutacin B-Ny266 was used as control [5]. Homology searches were carried out with the National
Figure 1

Multiple sequence alignment of mutacin H-29B with homologous type All lantibiotics. Only propeptides are shown. Conserved amino acids are in bold-type. Bacteriocin ruminococcin A is produced by Ruminococcus gnavus [25], butyrivibrioicin OR79A by Butyrivibrio fibrisolvens [26], salivaricin A by Streptococcus salivarius [27], lactacin 481 by Lactococcus lactis [28], variacin by Micrococcus varians [29], nukacin ISK-1 by Staphylococcus warneri [30], mutacin II (J-T8) [16], and streptococcin A-M49, A-FF22 and A-FF22’ are produced by Streptococcus pyogenes [31, 32].

Center of Biotechnology Information (nr-BLAST search, with Expect value = 0.01 and Search mode = multiple hits, 1 hits, 1 pass) [24].

Protein sequence accession number

The protein sequence data of mutacin H-29B appears in the Swiss-Prot and TrEMBL knowledgebase under the accession number P84110.

Abbreviations

Abu, 2-amino-5-butyric acid; ATCC, American Type Culture Collection; AU, arbitrary units; BM-Lan, β-methylanthionine; BMSEC, β-methyl-S-ethylcysteine; dhA, 2,3-dideoxy-d-alanine; dhB, 2,3-dideoxybutyryl; DSER, PTH-dithiothreitol adduct of dhA; Lan, lanthionine; MALDI-TOF MS, Matrix Assisted Laser Desorption Ionisation-Time of Flight Mass Spectroscopy; PTH, phenylthiohydantoin; RP-HPLC, reverse-phase high-pressure liquid chromatography; SEC, S-ethylcysteine; TFA, trifluoroacetic acid; TSAYE, trypticase soy agar yeast extract; TSBYE, trypticase soy broth yeast extract.

Authors’ contributions

Guillaume Nicolas participated in project conception, is the main manipulator of the experimental MS and sequencing data and drafted the manuscript. Helene Morency participated in the purification of the peptide mutacin H-29B. Gisèle LaPointe designed and supervised the molecular analyses and participated in manuscript preparation. Marc C. Lavoie conceived the study and participated in its design and coordination as well as manuscript preparation. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by the Natural Sciences and Engineering Research Council of Canada. We thank Laurent Smith of the Department of Biochemistry and Microbiology and Alain Gaudreau of INAF (Nutraceuticals and Functional Foods Institute) and the STELA Dairy Research Group of Université Laval for their technical assistance.

References

1. Jack RW, Tagg JR, Ray B: Bacteriocin of Gram-positive bacteria. Microbiol Rev 1995, 59:171-200.
2. Hamada S, Ooshima T: Production and properties of bacteriocins (mutacins) from Streptococcus mutans. Arch Oral Biol 1975, 20:641-648.
3. Mota-Meira M, LaPointe G, Lacroix C, Lavoie MC: MICs of mutacin B-Ny266, nisin A, vancomycin, and oxacillin against bacterial pathogens. Antimicrob Agents Chemother 2000, 44:24-29.
4. Morency H, Mota-Meira M, LaPointe G, Lacroix C, Lavoie MC: Comparison of the activity spectra against pathogens of bacterial strains producing a mutacin or a lantibiotic. Can J Microbiol 2001, 47:322-331.
5. Mota-Meira M, Lacroix C, LaPointe G, Lavoie MC: Purification and structure of the mutacin B-Ny266: a new lantibiotic produced by Streptococcus mutans. FEMS Lett 1997, 410:275-279.
6. Balakrishnan M, Simmonds RS, Carne A, Targ JR: Streptococcus mutans strain N produces a novel low molecular mass non-lantibiotic bacteriocin. FEMS Microbiol Lett 2001, E183:165-169.
7. Qi F, Chen P, Caufield PW: The group I strain of Streptococcus mutans, UA140, produces both the lantibiotic mutacin I and a nonlantibiotic bacteriocin, mutacin IV. Appl Environ Microbiol 2001, 67:15-21.
8. Yonezawa H, Kuramitsuka HK: Genetic analysis of a unique bacteriocin, Smb, produced by Streptococcus mutans G55. Antimicrob Agents Chemother 2005, 49:541-548.
9. McAuliffe O, Ross RP, Hill C: Lantibiotics: structure, biosynthesis and mode of action. FEMS Microbiol Rev 2001, 25:285-308.
10. Morency H, Trahan L, Lavoie MC: Preliminary grouping of mutacins. Can J Microbiol 1995, 41:826-831.
11. Bekal-Si Ali S, Hurtubise Y, Lavoie MC, LaPointe G: Diversity of Streptococcus mutans bacteriocins as confirmed by DNA analysis using specific molecular probes. Gene 2002, 283:125-131.
12. Novak J, Bourgeau G, Caufield PW, Parrot M, Norkates J, Lavoie M, Miller E: Biochemical analysis of a group II mutacin from Streptococcus mutans. Abstract of the ASM General Meeting No. A-44 1993.
13. Novak J, Caufield PW, Miller EJ: Isolation and biochemical characterization of a novel lantibiotic mutacin from Streptococcus mutans. J Bacterial 1994, 176:4316-4320.
14. Balakrishnan M, Simmonds RS, Killian M, Targ JR: Different bacteriocin activities of Streptococcus mutans reflect distinct phylogenetic lineages. J Med Microbiol 2002, 51:941-948.
15. Meyer HE, Heber M, Eisermann B, Korte H, Metzger JW, Jung G: Sequence analysis of lantibiotics: chemical derivatization procedures allow a fast access to complete Edman degradation. Anal Biochem 1994, 223:185-190.
16. Knurl RE, Chen P, Novak J, Kirk M, Barnes S, Baker J, Krishna NR, Caufield PW: Biochemical structural analysis of the lantibiotic mutacin II. J Biol Chem 2000, 275:15848-15850.
17. Parrot M, Caufield PW, Lavoie MC: Production of mutacin-like substances by Streptococcus mutans. Can J Microbiol 1989, 36:123-130.
18. Qi F, Chen P, Caufield PW: Purification and biochemical characterization of mutacin I from group I strain of Streptococcus mutans, CH43, and genetic analysis of mutacin I biosynthesis genes. Appl Environ Microbiol 2000, 66:3221-3229.
19. Hillman JD, Novak J, Sagura E, Gutierrez JA, Brooks A, Crowley PJ, Hess M, Azizi A, Leung K-P, Cvitkovitch D, Bleiweis AS: Genetic and biochemical analysis of mutacin 1140, a lantibiotic from Streptococcus mutans. Infect Immun 1998, 66:2743-2749.
20. Qi F, Chen P, Caufield PW: Purification of mutacin III from group III Streptococcus mutans UA787 and genetic analyses of mutacin III biosynthesis genes. Appl Environ Microbiol 1999, 65:3880-3887.
21. Woodruff WA, Novak J, Caufield PW: **Sequence analysis of mutA and mutM genes involved in the biosynthesis of the lantibiotic mutacin II in Streptococcus mutans.** Gene 1998, 206:37-43.
22. Chen P, Qi F, Novak J, Caufield PW: **The specific genes for lantibiotic mutacin II biosynthesis in Streptococcus mutans T8 are clustered and can be transferred en bloc.** Appl Environ Microbiol 1999, 65:1356-1360.
23. Nicolas G, Auger I, Beaudoin M, Halle F, Morency H, LaPointe G, Lavoie MC: **Improved methods for mutacin detection and production.** J Microbiol Methods 2004, 59:351-361.
24. Marchler-Bauer A, Anderson JB, DeWeese-Scott C, Fedorova ND, Geer LY, He S, Hurwitz DI, Jackson JD, Jacobs AR, Lanczycki CJ, Liebert CA, Liu C, Madel T, Marchler GH, Mazumder P, Nikolskaya AN, Panchenko AR, Rao BS, Shoemake BA, Simonyan V, Song JS, Thiessen PA, Vasudevan S, Wang Y, Yamashita RA, Yin JJ, Bryant SH: **CDD: a curated Entrez database of conserved domain alignments.** Nucleic Acids Res 2003, 31:383-387.
25. Dabard J, Bridonneau C, Phillipe C, Anglade P, Molle D, Nardi M, Ladiré M, Girardin H, Marcille F, Gomez A, Fons M: **Ruminococcin A, a new lantibiotic produced by a Ruminococcus gravis strain isolated from human feces.** Appl Environ Microbiol 2001, 67:4111-4118.
26. Kalmokoff ML, Lu D, Whitford MF, Teather RM: **Evidence for production of a new lantibiotic (butyrivibriocin OR79A) by the ruminal anaerobe Butyrivibrio fibrisolvens OR79: characterization of the structural gene encoding butyrivibriocin OR79A.** Appl Environ Microbiol 1999, 65:2128-2135.
27. Ross KF, Ronson CW, Tagg JR: **Isolation and characterization of the lantibiotic salivaricin A and its structural gene salA from Streptococcus salivarius 20P3.** Appl Environ Microbiol 1993, 59:2014-2021.
28. Piard JC, Kuijpers OP, Rollema HS, Desmazeaud Mj, de Yos WM: Structure, organization, and expression of the lct gene for lactacin 481, a novel lantibiotic produced by Lactococcus lactis. J Biol Chem 1993, 268:16361-16368.
29. Pridmore D, Rekhil N, Pittie AC, Suri B, Mollet B: **Variatcin, a new lantibionin-containing bacteriocin produced by Micrococcus varians: comparison to lactacin 481 of Lactococcus lactis.** Appl Environ Microbiol 1996, 62:1799-1802.
30. Sashihara T, Kimura H, Higuchi T, Adachi A, Matsusaki H, Sonomoto K, Ishizaki A: **Cloning of the gene encoding a novel lantibiotic, nukacin ISK-1, of Staphylococcus warneri.** J Fac Agr Kyushu Univ 2000, 45:149-161.
31. Hynes WL, Ferretti JJ, Tagg JR: **Cloning of the gene encoding streptococcin A-FF22, a novel lantibiotic produced by Streptococcus pyogenes, and determination of its nucleotide sequence.** Appl Environ Microbiol 1993, 59:1969-1974.
32. Hynes WL, Friend VL, Ferretti JJ: **Duplication of the lantibiotic structural gene in M-type 49 group A Streptococcus strains producing streptococcin A-M49.** Appl Environ Microbiol 1994, 60:2407-2409.